Sonnet Biotherapeutics, operating in the biotech field, has made a significant move in the crypto world. A merger agreement with Rorschach, the treasury management collective of the Hyperliquid ecosystem backed by Paradigm, has been put on the table. This step marks a new structure at the intersection of traditional biotechnology and decentralized finance protocols. Market observers assess that such hybrid models may increase in the upcoming period.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
12 Likes
Reward
12
4
Repost
Share
Comment
0/400
HashRateHustler
· 17h ago
Are these biotech companies starting to play with DeFi now? That's interesting.
View OriginalReply0
blocksnark
· 17h ago
Biotechnology combined with Decentralized Finance? This combo is a bit wild, but there is still something behind Paradigm.
View OriginalReply0
GovernancePretender
· 17h ago
Biotech and DeFi really need to combine, this trend is a bit wild.
View OriginalReply0
GasFeeCry
· 17h ago
Biotech combined with crypto, this combination is pretty powerful... but is Rorschach reliable?
Sonnet Biotherapeutics, operating in the biotech field, has made a significant move in the crypto world. A merger agreement with Rorschach, the treasury management collective of the Hyperliquid ecosystem backed by Paradigm, has been put on the table. This step marks a new structure at the intersection of traditional biotechnology and decentralized finance protocols. Market observers assess that such hybrid models may increase in the upcoming period.